Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Femasys Q3 2026 Results: Net Loss of $4.56M, Loss Widens

Femasys Inc. reported a decrease in sales for the nine months ended September 30, 2026, totaling $1,161,313 compared to $1,479,926 in the prior year period. The company significantly strengthened its balance sheet, ending the quarter with $23.9 million in cash and cash equivalents following financing activities, while maintaining an accumulated deficit of $154 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.40.7
Profit before tax-4.6-4.2
Net income-4.6-4.2
EPS (diluted, $ a share)$-0.53$-2.05

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-44.5%
Source

10-Q filed with the SEC, NASDAQ: FEMY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Femasys Inc: key numbers

Share price
$1.12Close, Nov 17
Market cap
$9.7M
Shares outstanding
8.66MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Femasys Inc

All →
4:48 PM ET 8-K
Financial Results

Femasys Financial Results

Femasys reported financial results for the third quarter of 2026, highlighting a slight increase in U.S. sales to $0.35 million despite overall sales declining due to international distributor order timing. The company completed a $30 million private placement in August to fund the build-out of its U.S. commercial team and support the FemBloc pivotal trial.

Term
Q3 2026

“We maintained a lean team and tightly managed resources as we prioritized financing from long-term institutional investors. Closing the $30 million in financing in mid-August 2026 represents an important turning point for Femasys.”

Kathy Lee-Sepsick, Founder and Chief Executive Officer

“These results and commercial recruitment progress give us strong confidence that deploying our team in target U.S. territories will broaden adoption and drive revenue growth.”

Kathy Lee-Sepsick, Founder and Chief Executive Officer
4:16 PM ET 8-K
Leadership Change

Femasys Leadership Change

Femasys Inc. announced the appointment of John Moorhead to its Board of Directors as a designee of Nantahala Capital Management, LLC, effective October 30, 2026. Simultaneously, Dr. Kenneth D. Eichenbaum resigned from the Board following the termination of Pointillist Partners LLC's board nomination rights. Mr. Moorhead, a former Chief Marketing Officer at Unilever's Seventh Generation, will serve as a Class II director and join the Audit and Compensation Committees.

Counterparty
Nantahala Capital Management, LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.